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During the last two decades, numerous studies have
demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) diminish the risk of
cardiovascular morbidity and mortality. Although these
studies have focused primarily on the ability of statins to
lower circulating levels of low-density lipoprotein cholesterol,
more recent research has shown that statins may protect the
vasculature via pleiotropic effects not directly related to lipid
lowering. These include adjustments in cell-signaling
pathways that play a role in atherogenesis and that affect the
expression of inflammatory elements, curtail oxidative stress,
and enhance endothelial function. More recently, researchers
have begun to explore whether these agents exert similar
beneficial effects in renal parenchymal and renovascular
disease. This review examines the available evidence that
dyslipidemia may augment the inflammatory reaction of
cytokines in patients with renal disease and that statins may
improve renal dysfunction by altering the response of the
kidney to dyslipidemia, even in persons with end-stage renal
disease on dialysis or with renal transplantation. In this
context, some data suggest that statin-mediated alterations
in inflammatory responses and endothelial function may
reduce proteinuria and the rate of progression of kidney
disease.
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More than 8 million people in the United States have chronic
kidney disease (CKD), as defined by the National Kidney
Foundation (glomerular filtration rate (GFR) o60. 0 ml/
min/1.73 m2 of body surface area for X3 months), and an
estimated 20 million have evidence of abnormal urinary
albumin excretion.1 The incidence of CKD continues to
climb, not only in the United States but also worldwide.
Cardiovascular disease (CVD) is the leading cause of death
in patients with CKD. In patients with end-stage renal disease
(ESRD) undergoing dialysis, CVD accounts for more than
40% of deaths.2 Even when CKD is mild or moderate in
nature and other cardiovascular risk factors are controlled
for, patients with CKD run a higher risk of CVD than those
with normal kidney function.3–5 In addition to traditional
risk factors for CVD, such as hypertension and dyslipidemia,
patients with CKD commonly have proteinuria, electrolyte
imbalances, inflammation, increased oxidative stress, anemia,
and alterations in nitric oxide (NO) production.
Conversely, renal impairment itself is a risk factor for
poorer outcomes in patients who have had a cardiovascular
event.6 Analysis of the Kaiser Permanente Renal Registry
revealed an independent, graded association between reduced
estimated GFR and cardiovascular events, hospitalization,
and mortality.5 Similarly, in a double-blind randomized
clinical trial of 14 527 patients with myocardial infarction and
heart failure or left ventricular dysfunction, there was a
progressive increase in CVD risk with declining estimated
GFRs. Thus, even mild impairment of GFR substantially
increases the risk for cardiovascular complications after a
myocardial infarction.6
In view of these facts, the National Kidney Foundation
urges clinicians to regard CKD as a CVD risk equivalent and
to manage patients in accordance with guidelines from the
National Cholesterol Education Program Adult Treatment
Panel III.3,7 Despite the multiple beneficial effects of statins
on CVD risk, only about a third of patients with CKD and
ESRD are currently being treated for hyperlipidemia.8 This is
in part related to the lack of evidence for the benefit of statins
on CVD risk in patients with stage 4 and 5 CKD.
KIDNEY DISEASE, CARDIOVASCULAR RISK, AND
DYSLIPIDEMIA
Evidence suggests that in the early stages of renal impair-
ment, dyslipidemia increases the likelihood of CKD and may
also accelerate its progression by promoting intrarenal
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atherogenesis and cellular impairment in the microvascula-
ture. Dyslipidemia in patients with CKD is typified by high
levels of very low-density lipoproteins, triglycerides, lipoprotei-
n(a), and small, dense (i.e., highly atherogenic) low-density
lipoprotein cholesterol (LDL-C) particles, and by low levels of
high-density lipoprotein cholesterol (HDL-C). This form of
dyslipidemia may contribute to atherosclerosis and the
progression of CKD via the direct toxic effects of lipids and
the inflammatory mechanisms common to both conditions.9–11
It has been posited that alterations in both the renal and
coronary microvasculature account, at least in part, for the
linkage between renal impairment and CVD. Studies of
coronary flow reserve in CKD patients without obstructive
coronary artery disease, for example, reveal a reduced
vasodilative capacity in the coronary arteries compared with
that in healthy controls; this finding suggests early impair-
ment in the microcirculation of both vascular beds.12 Preston
et al.13 noted that carotid artery intima-media thickness, a
measure of cardiovascular risk in the general population, was
significantly greater in patients with CKD. This phenomenon
was accompanied by increased levels of LDL-C and
diminished levels of HDL-C. The investigators surmized that
vascular changes occur early and at an accelerated rate during
the early stages of renal impairment and may be related to
dyslipidemia.13
INFLAMMATION AND THE PROGRESSION OF KIDNEY DISEASE
In addition to the effects of dyslipidemia on the renal
microvasculature, the presence of lipids in renal cells
upregulates intracellular signaling pathways involved in
inflammatory and fibrogenic responses, both of which are
implicated in progressive renal injury.14
Renal biopsies from patients with glomerular disease
indicate that lipoproteins accumulate in both glomerular and
mesangial cells and within the mesangial matrix,15 and
oxidized lipids are frequently found in biopsy specimens
from patients with renal disease.16 The presence of lipids on
renal glomeruli is believed to activate various growth factors,
which in turn cause mesangial cell proliferation and
mesangial matrix expansion. Mesangial cells bind both LDL
and oxidized LDL (ox-LDL), leading to yet more cell
proliferation via multiple downstream effects. For example,
LDL stimulates the expression of monocyte chemoattractant
protein-1 mRNA, which increases monocyte chemotactic
activity.17 LDL also stimulates the expression of fibronectin
mRNA and increases fibronectin protein concentrations,
which induces proliferation of mesangial matrix cells. In the
extracellular matrix, the cytotoxic effects of ox-LDL are
evidenced by its induction of podocyte apoptosis and its
ability to decrease Akt activity, deplete nephrin (an adhesion
molecule specific to the glomerular slit membrane), and
induce the retraction of cultured podocytes, which leads to
alteration in the glomerular size-selective barrier to proteins
and increased albumin diffusion.18
Both LDL and ox-LDL induce the expression of two
mediators – interleukin-6 and nuclear factor (NF)-kB – essential
to inflammation and mesangial cell proliferation. NF-kB has
been associated with inflammatory events involving glomer-
ulonephritis, as well as to the progression of CKD.19 It has
also been found to induce the expression of genes that encode
other cytokines, chemokines, interferons, growth factors, cell
adhesion molecules, and major histocompatibility complex
proteins involved in inflammation and proliferation.20
PLEIOTROPIC EFFECTS OF STATINS
Statins effectively reduce serum levels of LDL-C, a major
pathologic factor in CVD, and to a lesser extent, also raise
HDL-C levels. Preliminary data indicate that statins may
slow the progression of CKD by improving the lipid profile as
well as by affecting inflammatory cell-signaling pathways
that control vascular cell migration, proliferation, and
differentiation.
The principal action of statins is to impede cholesterol
synthesis by inhibiting HMG-CoA reductase, an enzyme that
controls the rate of cholesterol synthesis in the liver via the
mevalonate pathway. Mevalonate is a product of HMG-CoA
reductase. When less mevalonate is produced, serum levels of
LDL-C decline (Figure 1).
By impeding the production of mevalonate, statins also
exert immunomodulatory and anti-inflammatory effects
(Table 1).21–23 This is because mevalonate also serves as a
precursor for isoprenoids, a group of proteins whose post-
translation modification is generally required for other
proteins to fulfill their cellular functions.23 Statins specifically
block the synthesis of two isoprenoids – farnesylpyropho-
sphate and geranylpyrophosphate – that normally attach
post-translationally to intracellular signaling proteins, in-
cluding the guanosine triphosphatases – Rho, Rac, and Ras –
and the G-proteins.21 These signaling proteins, in turn,
facilitate the interaction between growth-factor receptors and
the cellular cytoskeleton.21 By blocking the synthesis of
farnesylpyrophosphate and geranylpyrophosphate, statins
prevent the anchoring of growth factors to the cell membrane
and cytoskeleton, thus hindering signal transduction to the
nucleus, activation of transcription factors, and cell prolif-
eration in the vascular endothelium.
Among their anti-inflammatory and antiproliferative
effects, statins reduce levels of monocyte chemoattractant
protein-1, interleukin-1b, tumor necrosis factor-a, trans-
forming growth factor-b, interleukin-6, platelet-derived
growth factor, NF-kB, vascular cell adhesion molecule-1,
intercellular adhesion molecule-1, fibronectin mRNA, and
mesangial proteins.21,23–27 Using cultured vascular smooth
muscle cells and endothelial cells, Dichtl et al.28 investigated
the effects of statins on transcription factors that regulate
inflammation and cell proliferation. They found that statins
downregulate the activation of NF-kB, activator protein-1,
and hypoxia-inducible factor-1a. Inhibition of NF-kB
activation has been shown to decrease the release of
monocyte chemoattractant protein-1 and to stimulate
apoptosis of vascular smooth muscle cells.28,29 In vitro
studies indicate that statins reduce the proliferation of renal
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tubular epithelium by impairment of activator protein-1
binding30 as well as by preventing monocytes from maturing
into macrophages, inducing apoptosis of these cells.31 Other
investigators32 have shown that by downregulating surface
integrin adhesion molecules and inactivating Rho guanosine
triphosphatases, statins prevent monocytes from adhering to
endothelial cells, thus blunting the earliest manifestations of
atherosclerosis.
Additionally, statins exert a positive influence on NO, a
potent vasodilator with apparent anti-inflammatory actions
and beneficial effects on platelet aggregation, neutrophil
adhesion, and cell proliferation.33 Statins have been shown to
upregulate and stabilize endothelial NO synthase (eNOS),
which increases the bioavailability of NO.21,23,34–38 Evidence
suggests that NO has a salutary effect in patients who have
undergone renal transplantation or who have nephrotoxic
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Figure 1 | Reproduced from Nuf.79
Table 1 | Antiinflammatory and immunologic effects of statins
Anti-inflammatory effects Immunomodulatory effects
Decrease ET-1 Decrease interferon gamma-induced MHC class II expression
Decrease IL-6 Decrease T-cell activation
Decrease VCAM-1 and ICAM-1 Decrease monocyte activation
Decrease PDGF Increase transplant survival?
Decrease NF-kB activation Increase resistance to complement
Decrease endothelial cell activation Increase inhibition of leukocyte function antigen-1
Decrease leukocyte-endothelial cell adhesion
Decrease proinflammatory cytokines (particularly MCP-1)
Decrease CRP
Increase NO
Increase PPAR-a
Induce apo A–I expression
Inhibit LDL oxidation
Inhibit histamine release by basophils
Apo A–I, apolipoprotein A–I; CRP, C-reactive protein; ET-1, endothelin-1; ICAM-1, intercellular adhesion molecule-1; IL-6, interleukin-6; LDL, low-density lipoprotein; MCP-1,
monocyte chemoattractant protein-1; MHC, major histocompatibility complex; NF-kB, nuclear factor kB; NO, nitric oxide; PPAR-a, peroxisome proliferator-activated
receptor-a; PDGF, platelet-derived growth factor; VCAM-1, vascular cell adhesion molecule-1.
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serum-induced glomerulonephritis or autoimmune tubular
interstitial nephritis.39 Statins also protect against the
oxidation of LDL and thereby reduce oxidative stress.35,36
The antioxidant effects of statins enhance endothelial
function and support normal vascular reactivity. Statins also
inhibit the proliferative effects of ox-LDL on mesangial
cells.26 Lastly, statins stabilize eNOS mRNA by inhibiting the
geranylgeranylation of Rho guanosine triphosphatase.40,41
This activity, in turn, reduces the level of surface protein
endothelin-1, a potent vasoconstrictor and mitogen.36
STATINS IN EXPERIMENTAL KIDNEY DISEASE
Experimental models of kidney disease suggest that statins
impede the progression of renal injury through their anti-
inflammatory and immunomodulatory effects. In cultured
human podocytes, for example, statins prevent ox-LDL-
mediated glomerular injury by stimulating Akt.18 Similarly,
low-dose atorvastatin has been shown to increase eNOS
activity and NO availability in aging rats, improving renal
dynamics, and conferring histologic protection of the tubule
after acute ischemic renal failure.42 Dahl salt-sensitive rats
experienced normalization of aortic eNOS and superoxide,
along with reduced left ventricular hypertrophy and protei-
nuria, after undergoing salt restriction and atorvastatin
therapy.38 The ability of statins to upregulate vascular eNOS
and inhibit oxidative stress may explain their capacity for
preventing end-organ injury in salt-sensitive hypertension.
In a rat model of glomerulonephritis, Yoshimura et al.43
showed that simvastatin suppressed mesangial cell prolifera-
tion, mesangial matrix expansion, and macrophage infiltra-
tion into the glomeruli. Simvastatin was also found to
decrease renal interstitial fibrosis, tubular activation, and
trans-differentiation in rats with unilateral ureteral obstruc-
tion,44 and was found to reduce interstitial fibrosis and levels
of monocyte chemoattractant protein-1 in salt-sensitive
hypertensive rats.45 Finally, lovastatin attenuated glomerular
macrophage infiltration and albuminuria in a rat model of
puromycin aminonucleoside nephrosis.46
EFFECTS OF DYSLIPIDEMIA AND STATINS IN RENALLY
IMPAIRED PATIENTS
CKD patients
Epidemiologic and clinical evidence support the notion that
dyslipidemia is a risk factor for the initiation of CKD and
that lipid lowering may slow disease progression.
The correlation between baseline lipid measures and rate
of decline in kidney function is well documented.11,47 In the
Physician’s Health Study,11 researchers traced the probability
of ensuing renal dysfunction (elevated creatinineX1.5 mg/dl
or estimated creatinine clearance (CrCl) p55 ml/min) in
4483 apparently healthy males (baseline plasma creatinine
level o1.5 mg/dl) who provided blood samples in 1982 and
1996. After 14 years, 134 subjects (3%) had an elevated
creatinine and 244 (5.4%) had reduced CrCl. The odds of
renal disease progression were directly related to baseline
blood lipid levels. In descending order, the relative risk for
creatinine elevation was 2.34 (95% confidence interval (CI),
1.34–4.07) in men with the highest quartile of total
cholesterol:HDL-C ratio (X6.8), 2.16 (95% CI, 1.22–3.80)
in men with the highest quartile of non-HDL-C (X196.1 mg/
dl), 2.16 (95% CI, 1.42–3.27) in men with HDL o40 mg/dl,
and 1.77 (95% CI, 1.10–2.86) in men with a total cholesterol
X240 mg/dl. Similar, although less pronounced associations,
were observed between baseline cholesterol parameters and
reduced CrCl.47
The Helsinki Heart Study documented an association
between dyslipidemia and progressive kidney disease in 2702
middle-aged dyslipidemic men.47 Renal function deteriorated
by a mean 3% over 5 years, and although hypertension
accelerated this change, the decline was faster by 20% in men
with an LDL:HDL ratio 44.4 compared to men with a ratio
o3.2. After multiple regression analyses, the only measures
having a significant effect on the observed phenomenon were
an increased LDL:HDL ratio (negative outcome) and an
increased HDL-C level (protective outcome).
Evidence that lipid-lowering agents might help preserve
renal function in patients with CKD comes from several
sources.48–55 A meta-analysis of 13 small, prospective,
controlled clinical trials examining the effects of antihyperli-
pidemic medications (primarily statins) on renal function,
albuminuria, or proteinuria showed that treatment signifi-
cantly slowed the rate of decline in GFR (0.16 ml/min/mo;
95% CI, 0.03–0.29 ml/min/mo; P¼ 0.008) versus controls.48
There was also a trend toward reduced proteinuria
(P¼ 0.077) and less progression toward ESRD in treated
subjects.
A prospective, controlled, open-label study found that
atorvastatin 10–40 mg/d reduced proteinuria and the rate of
progression of kidney disease in 56 patients with CKD,
proteinuria, and hypercholesterolemia who had been treated
with angiotensin-converting enzyme inhibitors, angiotensin
II type 1-receptor blockers, or a combination of the two
before random assignment to supplemental atorvastatin or
placebo.53 After 1 year, atorvastatin was associated with a
significant drop in urine protein excretion (from 2.270.1 to
1.271.0 g/24 h; Po0.01), whereas the decrease with placebo
was insignificant (from 2.070.1 to 1.870.1 g/24 h). Con-
versely, the placebo group experienced a marked decrease in
CrCl (from 5071.9 to 44.271.6 ml/min; Po0.01), whereas
the atorvastatin group showed only a slight fall (from 5171.8
to 49.871.7 ml/min; P¼NS).
Secondary and post hoc analyses of renal function in
landmark statin trials have also underscored the renoprotec-
tive effects of statins. A post hoc analysis of nearly 700
participants in the Cholesterol and Recurrent Events study,
for example, demonstrated parity in the rate of GFR decline
between pravastatin and placebo in patients with moderate
chronic renal insufficiency (estimated GFR o60 ml/min/
1.73 m2), but a significant difference in the rate of decline
with pravastatin (2.5 ml/min/1.73 m2 per year slower than in
placebo recipients; P¼ 0.0001) in those with severe CKD at
baseline (estimated GFR o40 ml/min/1.73 m2).49
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Similarly, a subgroup analysis of the Greek Atorvastatin
and Coronary Heart Disease Evaluation (GREACE) found
that statin treatment either prevented a decline in renal
function or significantly improved renal function.54 In
GREACE, the effects of dose-titrated atorvastatin 10–80 mg/
d on renal function were compared with those of ‘usual care’
(i.e., lifestyle changes and lipid-lowering agents, including
various statins) in previously untreated dyslipidemic patients
with coronary heart disease. At study end, CrCl had increased
by 12% (Po0.0001) in the atorvastatin group and by 4.9%
(P¼ 0.003) in the usual care patients who were given statins,
whereas it had declined by 5.2% (Po0.0001) in patients from
both groups who had either stopped taking statins or never
received them at all. The reasons for the increase in GFR in
the atorvastatin-treated group are unclear, but may be due to
improved availability of NO or decreased inflammation.
Whether this translates into structural benefits is uncertain at
the moment.
Excitement about potential renoprotective effects of
statins has been partially tempered by observations of
increased proteinuria with rosuvastatin therapy.56 During
the first year of post-marketing, rosuvastatin was more likely
to be associated with proteinuria than other statins. The
effect of rosuvastatin on proteinuria appears to be dose
related and it has been attributed to interference of the drug
with albumin and a-1 microglobulin reabsorption by renal
tubular cells.57,58 It is comforting however, that a meta-
analysis of renal function data from the rosuvastatin clinical
development program, in which a diverse group of 410 000
persons received recommended doses for up to 3.8 years,
showed that treated subjects had lower serum creatinine
levels as well as increased GFR compared with baseline, both
early and later in the course of treatment.55 Placebo
recipients, by contrast, showed no change in either serum
creatinine levels or GFR. The between-group differences were
independent of subjects’ hypertensive or diabetic status or
level of renal function (GFR X60 versus o60 ml/min/
1.73 m2), suggesting that rosuvastatin may arrest the
progression of CKD. In a recent report by Vidt et al.,50
retrospective analysis of a large clinical database showed
a highly significant increase in estimated GFR from
baseline after 6–8 weeks of treatment with rosuvastatin, in
conjunction with a decrease in estimated GFR in placebo-
treated patients. Beneficial effects were consistent across all
demographic subgroups, including in patients with estimated
GFR o60 ml/min/1.73 m2, patients with baseline proteinur-
ia, and patients with hypertension and/or diabetes, and these
effects were independent of the extent of lipid lowering.
In a 20-week, open-label trial, 91 CKD patients were
randomly assigned to rosuvastatin 10 mg/day or no lipid-
lowering therapy, and active treatment was associated with a
43% reduction in LDL-C, a 47% reduction in C-reactive
protein, and an 11% increase in GFR.51
More studies are needed to ascertain the effects of
rosuvastatin on proteinuria and hematuria in patients with
pre-existing CKD.
In the first United Kingdom Heart and Renal Protection
(UK-HARP) study,59 224 patients randomly assigned to
20 mg of simvastatin experienced a decrease of 18% in total
cholesterol, 24% in LDL-C, and 13% in triglycerides at 12
months. Proportional reductions in these lipids were similar
among patients categorized as predialysis, on dialysis, or
having a functioning renal transplant.59 Of note, the
investigators found statin therapy to be both safe and
tolerable in CKD patients, with no excess risk for liver
toxicity or creatine kinase elevation.
As with CVD, statins most likely retard the progression of
CKD by their lipid-modifying and anti-inflammatory effects
(Table 2).51,52,59–62 Tonolo et al.63 found that the effects of
simvastatin on decreasing urinary albumin excretion were
largely independent of LDL-C reduction. As cholestyramine
treatment had no effect on proteinuria, the authors
concluded that statins may have a direct beneficial effect on
the vasculature beyond that owing to lipid modification.
Two randomized, multicenter investigations are currently
underway to examine the long-term safety of statins in CKD
and in dialysis patients and to evaluate the extent to which
LDL-C reduction may improve cardiovascular risk and
survival in these patients. The Study of Heart and Renal
Protection(SHARP) is assessing outcomes in 9000 CKD and
ESRD patients given combination simvastatin/ezetimibe
therapy.64 The primary end point of SHARP is time to a
first major vascular event; secondary end points include
progression to ESRD, causes of death, major cardiac events,
Table 2 | Cardiovascular and renal risk-modifying effects of statins in patients with renal disease
Effect Reference
Lipid-modifying effects
Reduce TC levels Chang,52 Baigent,59 van den Akker60, Diepeveen61
Reduce LDL levels Verma,51 Baigent,59 van den Akker,60 Diepeveen,61 Ikejiri62
Reduce TG levels Baigent59, Diepeveen61
Reduce remnant lipoprotein and apolipoprotein levels van den Akker,60 Diepeveen,61 Ikejiri62
Increase LDL particle size Ikejiri62
Anti-inflammatory effects
Reduce CRP levels Verma,51 Chang52
Antioxidant effects
Reduce ox-LDL levels van den Akker,60 Diepeveen61
CRP, C-reactive protein; LDL, low-density lipoprotein; ox-LDL, oxidized low-density lipoprotein; TC, total cholesterol; TG, triglycerides.
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stroke, and hospitalization. The Prospective evaLuation of
proteinuriA and reNal function in diabetic and nondiabETic
patients with progressive renal disease (PLANET) studies will
examine the effects of rosuvastatin on proteinuria and renal
function in 690 CKD patients, 345 with diabetes, and 345 without
diabetes, all with moderate proteinuria, over a 1-year period.
Hopefully, these two studies will provide more definitive
evidence that treatment with statins may provide cardiovas-
cular and renal benefits in CKD patients. The PLANET study
will also resolve the controversy surrounding the effects of
rosuvastin on urinary protein excretion.
Dialysis patients
Almost 400 000 Americans are estimated to have ESRD.65
ESRD patients commonly experience accelerated atherogen-
esis and CVD. A number of studies suggest that vascular
disease in patients with ESRD has its origins in uremic factors
such as vascular calcification.13
Several small studies have shown that statin therapy improves
the cardiovascular risk profile of persons with ESRD.52,60–62
Improvements in risk factors notwithstanding, there is
only limited evidence to date that statin-induced changes in
the cardiovascular risk profile of ESRD patients translate
into improved cardiovascular outcomes. Data from two
retrospective studies indicated that statin use decreased all-
cause and cardiovascular mortality in dialysis patients.2,66
Patients who had used fibrates experienced no mortality
benefit. The cardiovascular-specific mortality rate was
61/1000 person-years for statin users and 88/1000 person-
years in non-users.
In contrast, the multicenter, randomized, double-blind
Deutsche Diabetes Dialyse Studie (4D) detected no mortality
benefit from atorvastatin in 1255 type II diabetic dialysis
patients with ESRD.67 Despite a median 42% reduction in
LDL-C from baseline levels of 80–190 mg/dl, atorvastatin
20 mg/d had no significant effect on the combined primary
end point of cardiovascular death, non-fatal myocardial
infarction, and stroke, or on all-cause mortality. Treatment
was associated with a reduced rate of all cardiac events
combined, but not of all cerebrovascular events, and
surprisingly, it increased the relative risk of fatal stroke
(relative risk 2.03; 95% CI, 1.05–3.93; P¼ 0.04).67 Thus, there
is inconclusive evidence that use of statins in dialysis patients
results in cardiovascular benefits.
One study currently in progress – the Use of Rosuvastatin
in subjects On Regular hemodialysis: an Assessment of
survival and cardiovascular events (AURORA) – is investigat-
ing the effects of rosuvastatin therapy on time to death from
any cause and time to major cardiovascular event in 42750
ESRD patients who are receiving chronic dialysis treatment,
regardless of baseline lipid levels.68 This double-blind,
randomized, placebo-controlled, multicenter trial is expected
to be completed in May of 2008. The AURORA and the
SHARP study will hopefully provide some definitive
information in regards to potential benefit of statins in the
dialysis population.
Kidney transplant patients
Hyperlipidemia affects up to 74% of kidney transplant
recipients,69 and it has been implicated in contributing to the
development of chronic allograft nephropathy and the
deterioration of renal transplant function.70. The use of
lipid-lowering agents in this population may be undertaken
not only to treat dyslipidemia and modify atherosclerotic
vascular disease, but also to improve cardiovascular outcomes
and perhaps even extend graft preservation.
An important factor causing chronic renal allograft
rejection appears to be incipient histologic changes in the
graft.70 The changes implicated in chronic allograft damage
include smooth muscle cell proliferation and the accumula-
tion of extracellular matrix, two characteristic features of
atherosclerosis. Interestingly, both phenomena may be
modulated by HMG-CoA reductase activity, which correlates
positively with cellular DNA synthesis.
Whether or not statins protect the renal allograft is
unknown. A rat model of chronic cyclosporine-induced
nephropathy has shown that administration of pravastatin
and losartan can attenuate inflammatory and fibrotic
processes.71 The action of the two drugs, which have
synergistic effects on the proliferation of vascular smooth
muscle cells and fibrotic processes, was shown to be
independent of any hypolipidemic or hypotensive properties.
However, the clinical evidence to support the therapeutic
efficacy of statins in transplantation settings is mixed. In a
prospective study of cardiac transplantation, patients given
pravastatin soon after surgery experienced less frequent
cardiac transplant rejection owing to hemodynamic com-
promise after 1 year than untreated individuals, demonstrat-
ing better survival and a lower incidence of coronary
vasculopathy.72 Similarly, a retrospective analysis of 77 renal
transplant recipients found that CrCl was significantly higher
at 12 months post-surgery among patients given statins than
among those who were not treated.73 Moreover, transplant
biopsies in the untreated group showed a higher fractional
interstitial area and collagen III deposition. The median time
to initiation of statin therapy in the study was 5 weeks. In
another study, renal transplant recipients randomly assigned
to pravastatin for 4 months had half the rate of acute
rejection as placebo recipients (25 versus 58%, Po0.01).69 By
contrast, no benefit on acute rejection with statins was
observed in a 90-day trial employing simvastatin immediately
after renal transplantation, starting at 2 weeks, even though
the levels of total cholesterol and LDL-C were significantly
lower in statin-treated patients than in those receiving a
fibrate or placebo (Pp0.001).74
No benefit on acute rejections was also observed in the
Assessment of Lescol in Renal Transplant trial.75 This was a
randomized, double-blind, placebo-controlled study of 2102
renal transplant patients with total cholesterol levels of
155–348 mg/dl who were randomly assigned to fluvastatin 40
or 80 mg versus placebo and followed up for 5–6 years.
Patients given fluvastatin experienced a 32% decrease in
LDL-C levels and a trend towards reduction in the risk of
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major adverse cardiac event, the primary end point for this
trial, although the difference compared with placebo was not
statistically significant (P¼ 0.139). Treatment with fluvastatin
demonstrated a 38% reduction in the risk of cardiac
death (P¼ 0.031), a 32% reduction in the risk of non-fatal
myo-cardial infarction (P¼ 0.050) and a 35% reduction in
the cumulative incidence of cardiac death or first non-fatal
MI (P¼ 0.005). However, there was no improvement in the
incidence of renal graft loss or doubling of serum creatinine
levels, nor was active therapy associated with less deteriora-
tion in the GFR over time than placebo.75 Patients taking
fluvastatin did not experience an increase in adverse effects,
reflecting its lower risk of interaction with calcineurin
inhibitors.76,77 Fluvastatin, pravastatin, and rosuvastatin
may be reasonable choices in renal transplant recipients
given their low degree of interaction with calcineurin
inhibitors.78
In summary, although statins reduce cardiovascular risk in
hyperlipidemic patients who have undergone renal trans-
plantation, their routine use to prevent acute or chronic
rejection is not supported by the evidence. Additional studies
are needed to determine what role statins might play in the
prevention of chronic allograft nephropathy.
CONCLUSION
CVD remains the principal cause of death in both the general
US population and CKD patients. Statins effectively decrease
the risk of CVD and events in the general population and in
patients with stage 1–3 CKD, but there is no good evidence
that they do so in patients with stage 4 and 5 CKD. A growing
body of evidence suggests that statins may reduce proteinuria
and also retard the progression of CKD. Additional
prospective, controlled, randomized trials are needed to
determine whether statins can improve cardiovascular out-
comes in patients with stage 4 and 5 CKD and in ESRD
patients on hemodialysis. Additional prospective, rando-
mized trials are also needed to determine whether statins are
truly renoprotective.
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